Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q2 2019 · 10-Q
Revenue$191.57M$191.57M+335.9% vs Q2 2018 Net Income$116.00M$116.00MN/M vs Q2 2018 EPS Diluted$1.26$1.26N/M vs Q2 2018 Operating Income$112,819,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$30,375,000N/M Margins · derivedOperating margin58.9%+111.8 pt vs Q2 2018
Net margin60.6%+113.8 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end